AU2020296972B2 - Continuous process for the preparation of anticholinergic drugs - Google Patents

Continuous process for the preparation of anticholinergic drugs Download PDF

Info

Publication number
AU2020296972B2
AU2020296972B2 AU2020296972A AU2020296972A AU2020296972B2 AU 2020296972 B2 AU2020296972 B2 AU 2020296972B2 AU 2020296972 A AU2020296972 A AU 2020296972A AU 2020296972 A AU2020296972 A AU 2020296972A AU 2020296972 B2 AU2020296972 B2 AU 2020296972B2
Authority
AU
Australia
Prior art keywords
bromide
anticholinergic agent
process according
anticholinergic
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020296972A
Other languages
English (en)
Other versions
AU2020296972A1 (en
Inventor
Marianna KATZ
Nuno TORRES LOURENÇO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hovione Scientia Ltd
Original Assignee
Hovione Scientia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71120199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2020296972(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hovione Scientia Ltd filed Critical Hovione Scientia Ltd
Publication of AU2020296972A1 publication Critical patent/AU2020296972A1/en
Application granted granted Critical
Publication of AU2020296972B2 publication Critical patent/AU2020296972B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020296972A 2019-06-17 2020-06-16 Continuous process for the preparation of anticholinergic drugs Active AU2020296972B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT115583A PT115583B (pt) 2019-06-17 2019-06-17 Processo contínuo para a preparação de medicamentos anticolinérgicos
PT115583 2019-06-17
PCT/GB2020/051448 WO2020254791A1 (en) 2019-06-17 2020-06-16 Continuous process for the preparation of anticholinergic drugs

Publications (2)

Publication Number Publication Date
AU2020296972A1 AU2020296972A1 (en) 2022-01-20
AU2020296972B2 true AU2020296972B2 (en) 2025-04-24

Family

ID=71120199

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020296972A Active AU2020296972B2 (en) 2019-06-17 2020-06-16 Continuous process for the preparation of anticholinergic drugs

Country Status (10)

Country Link
US (1) US20220251078A1 (https=)
EP (1) EP3982923B1 (https=)
JP (2) JP2022549545A (https=)
KR (1) KR20220024433A (https=)
CN (1) CN114206863A (https=)
AU (1) AU2020296972B2 (https=)
CA (1) CA3141271A1 (https=)
IL (1) IL288972A (https=)
PT (1) PT115583B (https=)
WO (1) WO2020254791A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117300A2 (en) * 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
WO2014027045A1 (en) * 2012-08-15 2014-02-20 Glaxo Group Limited Chemical process
US8865903B2 (en) * 2011-12-22 2014-10-21 Cerbios-Pharma Sa Continuous process for the alkylation of cyclic tertiary amines
WO2018087561A1 (en) * 2016-11-14 2018-05-17 Hovione Scientia Limited Process for the preparation of umeclidinium bromide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
WO2006117299A2 (en) 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Novel crystalline forms of tiotropium bromide
RU2453547C2 (ru) 2005-12-19 2012-06-20 Сикор Инк. Новые формы тиотропия бромида и способы их получения
US8163913B2 (en) 2005-12-19 2012-04-24 Sicor Inc. Forms of tiotropium bromide and processes for preparation thereof
JP5333342B2 (ja) 2009-06-29 2013-11-06 株式会社デンソー 半導体装置
PT106142B (pt) 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
CZ27764U1 (cs) 2014-08-22 2015-02-02 Zentiva, K.S. uMethanolový solvát umeclidinium bromidu
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006117300A2 (en) * 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
US8865903B2 (en) * 2011-12-22 2014-10-21 Cerbios-Pharma Sa Continuous process for the alkylation of cyclic tertiary amines
WO2014027045A1 (en) * 2012-08-15 2014-02-20 Glaxo Group Limited Chemical process
WO2018087561A1 (en) * 2016-11-14 2018-05-17 Hovione Scientia Limited Process for the preparation of umeclidinium bromide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MANDITY, I. M. et al., "Strategic Application of Residence-Time Control in Continuous-Flow Reactors", ChemistryOpen. 2015, vol. 4, pages 212-223. *

Also Published As

Publication number Publication date
PT115583A (pt) 2021-06-03
IL288972A (en) 2022-02-01
EP3982923B1 (en) 2024-05-15
EP3982923A1 (en) 2022-04-20
JP2025081547A (ja) 2025-05-27
WO2020254791A1 (en) 2020-12-24
CA3141271A1 (en) 2020-12-24
EP3982923C0 (en) 2024-05-15
KR20220024433A (ko) 2022-03-03
PT115583B (pt) 2022-05-02
AU2020296972A1 (en) 2022-01-20
JP2022549545A (ja) 2022-11-28
CN114206863A (zh) 2022-03-18
US20220251078A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
US11634377B2 (en) Fenfluramine compositions and methods of preparing the same
US4608377A (en) Quaternary 6,11-dihydro-dibenzo-[b,e]-thiepine-11-N-alkylnorscopine ethers having spasmolytic activity
KR101290893B1 (ko) 피롤리디늄 염의 제조 방법
EP2154136A1 (en) Quinuclidine carbonate derivatives and medicinal compositions thereof
IE59056B1 (en) 4-benzyl-1-(2h)-phthalazinone derivatives
CN102639531B (zh) 噻托溴铵的无水合物
AU2020296972B2 (en) Continuous process for the preparation of anticholinergic drugs
AU2017376363A1 (en) Class of bifunctional compounds with quaternary ammonium salt structure
WO2011161018A1 (en) Alkaloid aminoester derivatives and medicinal compositions thereof
EP2585457B1 (en) Alkaloid aminoester derivatives and medicinal composition thereof
ES2986962T3 (es) Proceso continuo para la preparación de fármacos anticolinérgicos
US20040242569A1 (en) Quatemary ammonium compounds
US20220402861A1 (en) A Crystalline form of (R)-terbutaline Hydrochloride
CN111909174B (zh) 吡啶酮衍生物的晶型及制备方法和应用
EP3468949B1 (en) Crystalline pharmaceutical co-crystals of glycopyrronium bromide with lactose
CN111574529A (zh) 蕈毒碱受体M3拮抗剂和β2-肾上腺素能受体激动剂桥环衍生物
JPH06510064A (ja) 置換イミダゾベンズオキサジン−１−オンの誘導体及び該誘導体の製造方法
US12398100B2 (en) Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
WO2025108293A1 (zh) 一种双功能气管扩张剂及其结晶和制备方法
HK1181769A (en) Process for the preparation of glycopyrronium chloride
HK1212989B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptro agonist activity
HK1212987A1 (zh) 具有毒蕈硷受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)